Concepedia

Ronald Shazer

RS

Statistics

Publications

16

Citations

682

H-Index

13

Active since

2005

Affiliations

Mirati Therapeutics (United States)(Current)

The University of Texas MD Anderson Cancer Center

The Ohio State University

Oncology Hematology Care

Rocky Mountain Cancer Centers

Ronald Shazer is an author at Mirati Therapeutics (United States) specializing in cancer therapeutics, oncology, and medicine.

ORCID

Top concepts

Publications per year

2005–2023

16

Publications

16

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 163 citations · Full text

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 78 citations · Full text

, , +7

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy

Pavlos Msaouel, Sangeeta Goswami, Peter F. Thall et al. · Science Translational Medicine · 2022 · 63 citations · Full text

Successful Treatment of Metastatic Androgen-Independent Prostate Carcinoma in a Transsexual Patient

Tanya B. Dorff, Ronald Shazer, Edward Macrohon Nepomuceno et al. · Clinical Genitourinary Cancer · 2007 · 59 citations

, , +5

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

Marc Oliva, Douglas B. Chepeha, Daniel Vilarim Araújo et al. · Journal for ImmunoTherapy of Cancer · 2021 · 51 citations · Full text

1–5 of 16